Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Lin, Shaojun ^a,b,c   Guo, Qiaojuan ^a,b,c   Wen, Jiangmei ^a,b,c   Li, Chao ^a,c   Lin, Jin ^a,b,c   Cui, Xiaofei ^a,b,c   Sang, Nianli ^d,e   Pan, Jianji ^a,b,c  

^a FUJIAN PROVINCIAL CANCER HOSPITAL   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c Fujian Provincial Key Laboratory of Translational Cancer Medicine   (China)

^d DREXEL UNIVERSITY   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Metastasis; Nasopharyngeal carcinoma; Prognosis; Radiation therapy; Retrospective; Stanniocalcin 2 (STC2)

Indexed keywords

HYPOCALCIN; STANNIOCALCIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TWO DIMENSIONAL CONVENTIONAL RADIATION THERAPY;

CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASAL MUCOSA; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899100112     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-26     Document Type: Article

References (40)

1. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF, J Clin Oncol 1998 16 4 1310 1317 9552031
2. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: Preliminary corroboration of the intergroup experience. Cooper JS, Lee H, Torrey M, Hochster H, Int J Radiat Oncol Biol Phys 2000 47 4 861 866 10.1016/S0360-3016(00)00558-7 10863053
3. Superiority of 5-year survival with chemoradiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup 0099 Phase III study: final report [Abstract]. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF, Proc Am Soc Clin Oncol 2001 20 227a
4. Prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T, Cancer 2002 94 8 2217 2223 10.1002/cncr.10473 12001120
5. A phase III study of adjuvant chemotherapy in advanced stage nasopharyngeal carcinoma patients. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY, Int J Radiat Oncol Biol Phys 2002 52 5 1238 1244 10.1016/S0360-3016(01)02781-X 11955734
6. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY, J Clin Oncol 2001 19 5 1350 1357 11230478
7. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Min HQ, J Clin Oncol 2005 23 6 1118 1124 10.1200/JCO.2005.12.081 15657403
8. Intensity-modulated radiation therapy for nasopharyngeal carcinoma: a review. Wang T, Riaz N, Cheng S, Lu J, Lee N, J Radiat Oncol 2012 1 129 146 10.1007/s13566-012-0020-4
9. Whole blood transcriptome correlates with treatment response in nasopharyngeal carcinoma. Zaatar AM, Lim C, Bong C, Lee MM, Ooi J, Suria D, Raman R, Chao S, Yang H, Neoh S, Liew CC, J Exp Clin Cancer Res 2012 31 76 10.1186/1756-9966-31-76 22986368
10. Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming. Qie S, Liang D, Yin C, Gu W, Meng M, Wang C, Sang N, Cell Cycle 2012 11 19 3679 3690 10.4161/cc.21944 22935705
11. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Law AY, Lai KP, Ip CK, Wong AS, Wagner GF, Wong CK, Exp Cell Res 2008 314 8 1823 1830 10.1016/j.yexcr.2008.03.001 18394600
12. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Law AY, Wong CK, Exp Cell Res 2010 316 3 466 476 10.1016/j.yexcr.2009.09.018 19786016
13. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Ito D, Walker JR, Thompson CS, Moroz I, Lin W, Veselits ML, Hakim AM, Fienberg AA, Thinakaran G, Mol Cell Biol 2004 24 21 9456 9469 10.1128/MCB.24.21.9456-9469.2004 15485913
14. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Law AY, Wong CK, Exp Cell Res 2010 316 20 3425 3434 10.1016/j.yexcr.2010.06.026 20619259
15. Regulation of glutamine synthetase in human breast carcinoma cells and experimental tumors. Collins CL, Wasa M, Souba WW, Abcouwer SF, Surgery 1997 122 2 451 463 discussion 463-464 10.1016/S0039-6060(97)90039-8 9288153
16. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ, Cancer Res 2002 62 5 1289 1295 11888893
17. Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Joensuu K, Heikkila P, Andersson LC, Cancer Lett 2008 265 1 76 83 10.1016/j.canlet.2008.02.022 18355956
18. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S, Nasu Y, Fujioka T, Shuin T, Nakamura Y, Nakagawa H, Cancer Sci 2009 100 5 914 919 10.1111/j.1349-7006.2009.01117.x 19298603
19. STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Kita Y, Mimori K, Iwatsuki M, Yokobori T, Ieta K, Tanaka F, Ishii H, Okumura H, Natsugoe S, Mori M, Ann Surg Oncol 2011 18 1 261 272 10.1245/s10434-010-1271-1 20734150
20. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Yokobori T, Mimori K, Ishii H, Iwatsuki M, Tanaka F, Kamohara Y, Ieta K, Kita Y, Doki Y, Kuwano H, Mori M, Ann Surg Oncol 2010 17 10 2601 2607 10.1245/s10434-010-1086-0 20422456
21. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K, Kato H, Asao T, Inoue H, Kuwano H, Mori M, Int J Cancer 2009 125 4 926 931 10.1002/ijc.24453 19415750
22. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Meyer HA, Tölle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, Johannsen M, Jung K, Kristiansen G, Eur Urol 2009 55 3 669 678 10.1016/j.eururo.2008.04.001 18450365
23. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Volland S, Kugler W, Schweigerer L, Wilting J, Becker J, Int J Cancer 2009 125 9 2049 2057 10.1002/ijc.24564 19582875
24. Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients. Song H, Xu B, Yi J, J Exp Clin Cancer Res 2012 31 35 10.1186/1756-9966-31-35 22537917
25. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ, Int J Radiat Oncol Biol Phys 2009 75 4 1071 1078 10.1016/j.ijrobp.2008.12.015 19362784
26. Study of antiapoptotic gene of oral carcinoma by using Bcl-2 oncogene. Kummoona R, Mohammad Sámi S, Al-Kapptan I, Al-Muala H, J Oral Pathol Med 2008 37 6 345 351 10.1111/j.1600-0714.2007.00624.x 18248353
27. MTA1 promotes nasopharyngeal carcinoma growth in vitro and in vivo. Song Q, Zhang H, Wang M, Song W, Ying M, Fang Y, Li Y, Chao Y, Zhu X, J Exp Clin Cancer Res 2013 32 1 54 10.1186/1756-9966-32-54 23941622
28. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. Xu L, Pan J, Wu J, Pan C, Zhang Y, Lin S, Yang L, Chen C, Zhang C, Zheng W, Lin S, Ni X, Kong FM, Radiother Oncol 2010 96 1 94 99 10.1016/j.radonc.2010.04.006 20435361
29. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW, Cancer Res 2004 64 21 7985 7994 10.1158/0008-5472.CAN-04-1525 15520206
30. Tumor vascular proteins as biomarkers in ovarian cancer. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos R, Liotta LA, Gimotty PA, Coukos G, J Clin Oncol 2007 25 7 852 861 10.1200/JCO.2006.08.8583 17327606
31. Stanniocalcin 2 expression is regulated by hormone signaling and negatively affects breast cancer cell viability in vitro. Raulic S, Ramos-Valdes Y, DiMattia GE, J Endocrinol 2008 197 3 517 529 10.1677/JOE-08-0043 18492817
32. mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Yamamura J, Miyoshi Y, Tamaki Y, Taguchi T, Iwao K, Monden M, Kato K, Noguchi S, Cancer Sci 2004 95 11 887 892 10.1111/j.1349-7006. 2004.tb02198.x 15546506
33. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM, Clin Cancer Res 2007 13 11 3164 3173 10.1158/1078-0432.CCR-07-0224 17545519
34. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ, J Clin Oncol 2001 19 18 3817 3827 11559719
35. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Ann Oncol 2007 18 7 1133 1144 10.1093/annonc/mdm271 17675394
36. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Meng M, Chen S, Lao T, Liang D, Sang N, Cell Cycle 2010 9 19 3921 3932 10.4161/cc.9.19.13139 20935507
37. Carbon source metabolism and its regulation in cancer cells. Yin C, Qie S, Sang N, Crit Rev Eukaryot Gene Expr 2012 22 1 17 35 10.1615/ CritRevEukarGeneExpr.v22.i1.20 22339657
38. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, de Marzo AM, van Eyk JE, Mendell JT, Dang CV, Nature 2009 458 7239 762 765 10.1038/nature07823 19219026
39. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. Qie S, Chu C, Li W, Wang C, Sang N, J Cell Biochem 2014 115 498 509 10.1002/jcb.24684 24122876
40. Effects of histone deacetylase inhibitors on HIF-1. Liang D, Kong X, Sang N, Cell Cycle 2006 5 21 2430 2435 10.4161/cc.5.21.3409 17102633